Previous close | 37.89 |
Open | 37.86 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 37.84 - 38.64 |
52-week range | 33.56 - 48.88 |
Volume | |
Avg. volume | 1,373,731 |
Market cap | 50.504B |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | 47.56 |
EPS (TTM) | 0.81 |
Earnings date | 25 July 2024 |
Forward dividend & yield | 0.23 (0.61%) |
Ex-dividend date | 27 May 2024 |
1y target est | 45.00 |
NEW YORK, May 14, 2024--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an expansion of its relationship with Worldwide Clinical Trials ("Worldwide"), a full-service global contract research organization (CRO). The agreement will facilitate data-driven decision-making across Worldwide’s entire clinical operations with the implementation of Medidata AI and enable Worldwide to support customers by reducing trial ti
Press ReleaseVELIZY-VILLACOUBLAY, France — May 14, 2024 JLR and Dassault Systèmes Extend Partnership, Deploying the 3DEXPERIENCE Platform for All Vehicle Programs Worldwide Five-year partnership marks the next phase of their long-standing collaboration to drive the automaker’s transformation for a good and responsible businessMore than 18,000 users globally will utilize virtual twins to increase the efficiency of vehicle engineering and digital manufacturing, save time, and reduce waste and cost
VELIZY-VILLACOUBLAY, France, May 14, 2024--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that it has extended its long-term strategic partnership with JLR for five years, heralding a new era of digital transformation at the automaker that will drive improved efficiency, collaborative innovation and sustainability throughout the enterprise.